Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair loss affects confidence, with discussions on treatments like finasteride, minoxidil, and RU58841. Emphasis is placed on self-acceptance and building confidence beyond appearance.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

Microneedling with RU58841 may not be necessary since RU works topically by occupying receptors before DHT binds. RU58841 is a topical anti-androgen.

A 51-year-old shared progress on hair regrowth using topical Minoxidil and Finasteride over four months, noting significant improvement and plans for future hair transplants. The user emphasized the benefits of modern treatments and societal changes in attitudes towards hair loss.

A 17-year-old improved his hairline using minoxidil and derma stamping, planning to start finasteride at 18. He received advice on dosing and potential side effects to maintain results.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.

Amplifica's AMP-303 showed a modest increase in hair growth, but results were inconsistent and potentially misleading. Hyaluronic acid and osteopontin are being explored for hair growth, with varying effects on different hair types and conditions.

PP405 aims to reactivate hair follicle stem cells to promote hair growth, but its effectiveness is debated. Some users are skeptical, citing past failures of similar treatments and questioning the company's claims.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

A 28-year-old male experiencing early male pattern baldness is considering using Pyrilutamide (KX-826) as an alternative to finasteride due to side effects. He seeks to maintain his current hair without regrowth and is concerned about potential side effects like reduced libido.

The conversation discusses using RU58841 for hair loss, with OP applying a 5% premixed solution from Receptorchem daily. Users express skepticism about the rapid results and inquire about other treatments and costs.

The conversation discusses the use of RU58841 for hair loss, with concerns about its legality in Germany and potential legal consequences. Alternatives like finasteride and dutasteride are mentioned, with some users questioning the effectiveness and safety of RU58841.

Hair loss concerns and treatments like Minoxidil and Finasteride are humorously discussed. The community's quirks and dedication to battling hair loss are highlighted.

Belgium disagrees with the EMA and does not authorize the 1 mg oral form of finasteride for androgenic alopecia, citing a negative benefit-risk ratio. Despite this, some individuals in Belgium can still obtain finasteride through prescriptions, and there is debate over its mental health risks versus its benefits for hair loss and other health issues.

Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.

An 18-year-old is experiencing positive hair regrowth results using 2.5mg minoxidil, 0.5mg finasteride daily, and dermarolling twice a week. They are satisfied with the progress and hope for continued improvement.

RU58841 is absorbed systemically in humans, contradicting claims it stays local, but no harm is proven. Alternatives like CB-03-01 or KX-826, especially with finasteride, are suggested for safety.

The user had a hair transplant with 2,000 grafts and used topical finasteride, minoxidil, 2.5mg oral minoxidil, and low-level laser therapy (LLLT) for hair regrowth. They experienced significant improvement over six months, with some dark circles as a side effect.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

A user is considering a hair transplant for density and is unsure whether to choose Reviva or Darling Buds, with Reviva being cheaper. Another user advises against Reviva due to poor experiences and suggests considering medication for hair density instead.

Bee venom at 0.001% concentration was more effective than 2% minoxidil in promoting hair growth in mice, possibly due to increased growth factors and reduced inflammation. Caution is advised due to potential allergic reactions and the reliance on animal data.

Verteporfin, combined with microneedling, shows promise for hair regrowth by allowing hair follicles to grow in wounds, but it's expensive and painful. Pai-1 inhibitors may also help prevent hair loss by degrading fibrosis, and some users continue using minoxidil alongside these treatments.

The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.

A 27-year-old experienced significant hair regrowth after a hair transplant with 4349 grafts, supported by minoxidil and finasteride, improving his confidence. He plans to update on further progress at 9–12 months.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

Finasteride and minoxidil treatments plateaued after 10 months, leading users to explore additional options like microneedling and low-level laser therapy (LLT) caps, though many are skeptical of the effectiveness and marketing of LLT devices like Kiierr. Users express frustration with the lack of clear recommendations from dermatologists and the prevalence of marketing hype over genuine reviews.

Some embrace baldness, while others promote treatments like minoxidil and finasteride. Opinions differ on accepting baldness versus pursuing hair regrowth.